| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1029602734 |
| P356 | DOI | 10.1186/S13024-015-0012-0 |
| P932 | PMC publication ID | 4404240 |
| P698 | PubMed publication ID | 25888232 |
| P5875 | ResearchGate publication ID | 275101898 |
| P50 | author | Dong-Kug Choi | Q61120429 |
| P2093 | author name string | Sandeep Vasant More | |
| P2860 | cites work | Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain | Q22001491 |
| A review of Parkinson's disease | Q22242927 | ||
| Mechanisms for selection of basic motor programs – roles for the striatum and pallidum | Q22337301 | ||
| Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain | Q24299523 | ||
| The capsaicin receptor: a heat-activated ion channel in the pain pathway | Q24322558 | ||
| Brain monoglyceride lipase participating in endocannabinoid inactivation | Q24533828 | ||
| Autophagy, mitochondria and oxidative stress: cross-talk and redox signalling | Q24608960 | ||
| Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities | Q24623282 | ||
| GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current | Q24653442 | ||
| Calcium signaling cascade links dopamine D1-D2 receptor heteromer to striatal BDNF production and neuronal growth | Q24656080 | ||
| Looking for the role of cannabinoid receptor heteromers in striatal function | Q24658338 | ||
| The orphan receptor GPR55 is a novel cannabinoid receptor | Q24670137 | ||
| Anandamide and vanilloid TRPV1 receptors | Q24672354 | ||
| Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor | Q24672600 | ||
| The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin | Q24676808 | ||
| A novel acylglycerol kinase that produces lysophosphatidic acid modulates cross talk with EGFR in prostate cancer cells | Q24678857 | ||
| Novel cannabinoid receptors | Q24681482 | ||
| Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants | Q24685540 | ||
| Cellular and molecular mediators of neuroinflammation in the pathogenesis of Parkinson's disease | Q26849232 | ||
| Parsing the players: 2-arachidonoylglycerol synthesis and degradation in the CNS | Q26853436 | ||
| Presynaptically located CB1 cannabinoid receptors regulate GABA release from axon terminals of specific hippocampal interneurons | Q28144567 | ||
| Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains | Q28189423 | ||
| Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets | Q28203208 | ||
| CB1 cannabinoid receptors and on-demand defense against excitotoxicity | Q28207143 | ||
| Cannabinoids protect astrocytes from ceramide-induced apoptosis through the phosphatidylinositol 3-kinase/protein kinase B pathway | Q28215554 | ||
| Structure of a cannabinoid receptor and functional expression of the cloned cDNA | Q28240076 | ||
| Pharmacotherapeutic modulation of the endocannabinoid signalling system in psychiatric disorders: drug-discovery strategies | Q28241318 | ||
| Identification of GPR55 as a lysophosphatidylinositol receptor | Q28244299 | ||
| N-arachidonoyl-dopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors | Q28244889 | ||
| Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons | Q28245016 | ||
| Cultured rat microglial cells synthesize the endocannabinoid 2-arachidonylglycerol, which increases proliferation via a CB2 receptor-dependent mechanism | Q28252850 | ||
| Functional neuroanatomy of the endocannabinoid system | Q28254682 | ||
| Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis | Q28268078 | ||
| Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study | Q28273200 | ||
| Presynaptic monoacylglycerol lipase activity determines basal endocannabinoid tone and terminates retrograde endocannabinoid signaling in the hippocampus | Q28286042 | ||
| Adenosine-cannabinoid receptor interactions. Implications for striatal function | Q28286488 | ||
| Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors | Q28292914 | ||
| Molecular characterization of a peripheral receptor for cannabinoids | Q28298338 | ||
| International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂ | Q28298445 | ||
| Cannabinoid receptor agonists reduce the short-term mitochondrial dysfunction and oxidative stress linked to excitotoxicity in the rat brain | Q46807435 | ||
| Glial expression of cannabinoid CB(2) receptors and fatty acid amide hydrolase are beta amyloid-linked events in Down's syndrome | Q46859134 | ||
| Strain differences in the expression of endocannabinoid genes and in cannabinoid receptor binding in the brain of Lewis and Fischer 344 rats. | Q46922174 | ||
| Motor cortex plasticity in Parkinson's disease and levodopa-induced dyskinesias. | Q46943000 | ||
| Immunolocalization of CB1 receptor in rat striatal neurons: a confocal microscopy study. | Q47242856 | ||
| Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice | Q47994629 | ||
| Selective CB2 receptor agonism protects central neurons from remote axotomy-induced apoptosis through the PI3K/Akt pathway. | Q48028956 | ||
| Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors | Q48087305 | ||
| The endocannabinoid system in rat gliosomes and its role in the modulation of glutamate release. | Q48089129 | ||
| Anandamide activation of CB1 receptors increases spontaneous bursting and oscillatory activity in the thalamus | Q48126877 | ||
| The CB1 cannabinoid receptor mediates excitotoxicity-induced neural progenitor proliferation and neurogenesis | Q48143381 | ||
| Opposing control of cannabinoid receptor stimulation on amyloid-beta-induced reactive gliosis: in vitro and in vivo evidence | Q48148192 | ||
| Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats | Q48192232 | ||
| Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology | Q34417710 | ||
| Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra | Q34421920 | ||
| Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives | Q34426072 | ||
| Neuroprotective properties of cannabigerol in Huntington's disease: studies in R6/2 mice and 3-nitropropionate-lesioned mice. | Q34440282 | ||
| Cannabinoids in experimental stroke: a systematic review and meta-analysis. | Q34452972 | ||
| The CB1 cannabinoid receptor agonist reduces L-DOPA-induced motor fluctuation and ERK1/2 phosphorylation in 6-OHDA-lesioned rats | Q34482483 | ||
| Brain cannabinoid systems as targets for the therapy of neurological disorders | Q34492167 | ||
| CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. | Q34504178 | ||
| Cannabinoids and neuroprotection | Q34520143 | ||
| AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis | Q34539350 | ||
| Cannabinoids: potential anticancer agents | Q34542671 | ||
| Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation | Q34570786 | ||
| Type-1 (CB1) cannabinoid receptor promotes neuronal differentiation and maturation of neural stem cells | Q34571086 | ||
| Circuits and circuit disorders of the basal ganglia | Q34599488 | ||
| Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. | Q34602111 | ||
| CB1-independent inhibition of dopamine transporter activity by cannabinoids in mouse dorsal striatum | Q34605794 | ||
| Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer's disease | Q34627188 | ||
| Oxidative metabolism of endocannabinoids | Q34673106 | ||
| Microarray and pathway analysis reveal distinct mechanisms underlying cannabinoid-mediated modulation of LPS-induced activation of BV-2 microglial cells | Q34700334 | ||
| Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system | Q34745063 | ||
| The endogenous cannabinoid system and the basal ganglia. biochemical, pharmacological, and therapeutic aspects. | Q34786832 | ||
| Trpv1 reporter mice reveal highly restricted brain distribution and functional expression in arteriolar smooth muscle cells | Q34929688 | ||
| Acute neuronal injury, excitotoxicity, and the endocannabinoid system | Q34995079 | ||
| Cannabinoid activation of peroxisome proliferator-activated receptors: potential for modulation of inflammatory disease. | Q35008120 | ||
| Temporal changes of CB1 cannabinoid receptor in the basal ganglia as a possible structure-specific plasticity process in 6-OHDA lesioned rats. | Q35014951 | ||
| CB1 cannabinoid receptor signalling in Parkinson's disease | Q35054346 | ||
| Commentary: Functional Neuronal CB2 Cannabinoid Receptors in the CNS | Q35107820 | ||
| Distribution of mRNA for vanilloid receptor subtype 1 (VR1), and VR1-like immunoreactivity, in the central nervous system of the rat and human | Q35120095 | ||
| Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson's disease | Q35193305 | ||
| Recruitment of prefrontal cortical endocannabinoid signaling by glucocorticoids contributes to termination of the stress response | Q35229784 | ||
| The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders | Q35586641 | ||
| The basal ganglia and motor control | Q35593766 | ||
| CB2 cannabinoid receptors promote neural progenitor cell proliferation via mTORC1 signaling | Q35668816 | ||
| The cannabinoid agonist WIN55212-2 decreases L-DOPA-induced PKA activation and dyskinetic behavior in 6-OHDA-treated rats | Q35740152 | ||
| Excitability of prefrontal cortical pyramidal neurons is modulated by activation of intracellular type-2 cannabinoid receptors | Q35807657 | ||
| CB1 Cannabinoid Receptor Expression in the Striatum: Association with Corticostriatal Circuits and Developmental Regulation | Q35820005 | ||
| Endocannabinoid-dopamine interactions in striatal synaptic plasticity | Q35898412 | ||
| Update on the role of cannabinoid receptors after ischemic stroke | Q35915645 | ||
| Synapse type-independent degradation of the endocannabinoid 2-arachidonoylglycerol after retrograde synaptic suppression. | Q36132823 | ||
| Differential transcriptional profiles mediated by exposure to the cannabinoids cannabidiol and Δ9-tetrahydrocannabinol in BV-2 microglial cells | Q36176444 | ||
| α-Synuclein induces alterations in adult neurogenesis in Parkinson disease models via p53-mediated repression of Notch1. | Q36234694 | ||
| Anti-dyskinetic effects of cannabinoids in a rat model of Parkinson's disease: role of CB(1) and TRPV1 receptors. | Q36248857 | ||
| Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression | Q36358055 | ||
| Effects on cell viability. | Q36441223 | ||
| Identification of the sites of 2-arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area. | Q36452302 | ||
| Programming of neural cells by (endo)cannabinoids: from physiological rules to emerging therapies. | Q36612284 | ||
| Mutant α-synuclein and aging reduce neurogenesis in the acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. | Q36641684 | ||
| Cannabinoid CB2 receptor: a new target for controlling neural cell survival? | Q36671508 | ||
| Endocannabinoid system: potential novel targets for treatment of schizophrenia | Q36675661 | ||
| Drug discovery in Parkinson's disease-Update and developments in the use of cellular models | Q36680414 | ||
| Immune control by endocannabinoids - new mechanisms of neuroprotection? | Q36695436 | ||
| The emerging functions of endocannabinoid signaling during CNS development. | Q36707633 | ||
| The endocannabinoid system in targeting inflammatory neurodegenerative diseases | Q36756837 | ||
| Dopamine-mediated regulation of corticostriatal synaptic plasticity. | Q36762821 | ||
| The endocannabinoid system and neurogenesis in health and disease. | Q36778571 | ||
| Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat. | Q36861976 | ||
| Endocannabinoids in basal ganglia circuits: implications for Parkinson disease | Q36884599 | ||
| Role of cannabinoids and endocannabinoids in cerebral ischemia | Q36967863 | ||
| Cannabinoids and neuroprotection in basal ganglia disorders. | Q36977766 | ||
| Differential distribution of diacylglycerol lipase-alpha and N-acylphosphatidylethanolamine-specific phospholipase d immunoreactivity in the superficial spinal dorsal horn of rats. | Q36990238 | ||
| Cannabinoids and neuroprotection in motor-related disorders | Q37066184 | ||
| Cannabinoid CB(2) receptor activation decreases cerebral infarction in a mouse focal ischemia/reperfusion model | Q37087780 | ||
| Endocannabinoid-dependent plasticity at GABAergic and glutamatergic synapses in the striatum is regulated by synaptic activity | Q37140712 | ||
| The cannabinoid system in Parkinson's disease: multiple targets to motor effects | Q37146722 | ||
| Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death | Q37192723 | ||
| Neurotrophic factors and structural plasticity in addiction | Q37223964 | ||
| Endocannabinoid signaling in microglial cells | Q37250243 | ||
| Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease. | Q37253331 | ||
| The endocannabinoid system in Parkinson's disease | Q37264881 | ||
| WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. | Q37371387 | ||
| Heteromeric dopamine receptor signaling complexes: emerging neurobiology and disease relevance | Q37379456 | ||
| NADPH oxidase and the degeneration of dopaminergic neurons in parkinsonian mice | Q37393199 | ||
| The endocannabinoid system as a target for the treatment of motor dysfunction | Q37394164 | ||
| Cannabinoid system in neurodegeneration: new perspectives in Alzheimer's disease | Q37489960 | ||
| The cannabinoid CB₂ receptor agonist AM1241 enhances neurogenesis in GFAP/Gp120 transgenic mice displaying deficits in neurogenesis | Q37522883 | ||
| Selective CB2 receptor activation ameliorates EAE by reducing Th17 differentiation and immune cell accumulation in the CNS | Q37531460 | ||
| Signal transduction of the CB1 cannabinoid receptor | Q37557059 | ||
| Cannabinoids and Parkinson's disease. | Q37617450 | ||
| Changes in CB(1) and CB(2) receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias | Q37637769 | ||
| Functionally selective cannabinoid receptor signalling: therapeutic implications and opportunities | Q37703507 | ||
| The endocannabinoid system as a target for the treatment of neuronal damage | Q37709370 | ||
| Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas | Q37752096 | ||
| The Multiplicity of Action of Cannabinoids: Implications for Treating Neurodegeneration | Q37793366 | ||
| Homeostatic changes of the endocannabinoid system in Parkinson's disease | Q37853933 | ||
| Prospects for cannabinoid therapies in basal ganglia disorders | Q37872326 | ||
| Therapeutic potential of cannabinoids in the treatment of neuroinflammation associated with Parkinson's disease | Q37893672 | ||
| Phytocannabinoids as novel therapeutic agents in CNS disorders. | Q37933589 | ||
| Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? | Q38012845 | ||
| The role of bioactive compounds on the promotion of neurite outgrowth. | Q38016042 | ||
| TRPV1: a stress response protein in the central nervous system. | Q38022033 | ||
| Adult neurogenesis in Parkinson's disease | Q38024276 | ||
| The neuroprotective role of endocannabinoids against chemical-induced injury and other adverse effects | Q38072364 | ||
| The influence of cannabinoids on generic traits of neurodegeneration | Q38156518 | ||
| Neuroimmmune interactions of cannabinoids in neurogenesis: focus on interleukin-1β (IL-1β) signalling | Q38164390 | ||
| Dyskinesia in Parkinson's disease: mechanisms and current non-pharmacological interventions | Q38207680 | ||
| Functions of the CB1 and CB 2 receptors in neuroprotection at the level of the blood-brain barrier | Q38220272 | ||
| Direct and indirect pathways of basal ganglia: a critical reappraisal | Q38234309 | ||
| Neural stem cells in Parkinson's disease: a role for neurogenesis defects in onset and progression | Q38268886 | ||
| Rising stars: modulation of brain functions by astroglial type-1 cannabinoid receptors | Q38276026 | ||
| A diacylglycerol lipase-CB2 cannabinoid pathway regulates adult subventricular zone neurogenesis in an age-dependent manner | Q38289958 | ||
| A new generation fatty acid amide hydrolase inhibitor protects against kainate-induced excitotoxicity | Q34011553 | ||
| Levodopa motor complications in Parkinson's disease | Q34070854 | ||
| Quantification of brain endocannabinoid levels: methods, interpretations and pitfalls | Q34098167 | ||
| Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington's disease. | Q34098292 | ||
| Protective effects of the synthetic cannabinoids CP55,940 and JWH-015 on rat brain mitochondria upon paraquat exposure | Q34118397 | ||
| Endocannabinoid signaling in the brain | Q34125520 | ||
| Nonpsychotropic cannabinoid receptors regulate microglial cell migration. | Q34179008 | ||
| CB2 Cannabinoid receptors as a therapeutic target-what does the future hold? | Q34186015 | ||
| Cannabinoid-1 receptor gene deletion has a compartment-specific affect on the dendritic and axonal availability of μ-opioid receptors and on dopamine axons in the mouse nucleus accumbens | Q34197458 | ||
| Effects of cannabinoids Δ(9)-tetrahydrocannabinol, Δ(9)-tetrahydrocannabinolic acid and cannabidiol in MPP+ affected murine mesencephalic cultures | Q34273763 | ||
| Autophagy of mitochondria: a promising therapeutic target for neurodegenerative disease | Q34287719 | ||
| Anandamide: some like it hot. | Q34296080 | ||
| Endocannabinoid signaling and synaptic function | Q34304094 | ||
| Pathophysiology of levodopa-induced dyskinesia: potential for new therapies | Q34325365 | ||
| Survey on cannabis use in Parkinson's disease: subjective improvement of motor symptoms | Q34349067 | ||
| Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study | Q34358022 | ||
| The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons | Q34380089 | ||
| Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study | Q34409345 | ||
| Evidence for novel cannabinoid receptors | Q34415409 | ||
| Pharmacological treatment of Parkinson disease: a review | Q34416640 | ||
| Distribution of neuronal cannabinoid receptor in the adult rat brain: a comparative receptor binding radioautography and in situ hybridization histochemistry | Q38331458 | ||
| A simple method for simultaneous determination of N-arachidonoylethanolamine, N-oleoylethanolamine, N-palmitoylethanolamine and 2-arachidonoylglycerol in human cells. | Q38927583 | ||
| Cannabinoid receptors CB1 and CB2 form functional heteromers in brain | Q39359086 | ||
| Cannabinoid CB(2) receptors modulate ERK-1/2 kinase signalling and NO release in microglial cells stimulated with bacterial lipopolysaccharide | Q39467487 | ||
| Inhibition of phosphodiesterases rescues striatal long-term depression and reduces levodopa-induced dyskinesia. | Q39801798 | ||
| MK-801 inhibits L-DOPA-induced abnormal involuntary movements only at doses that worsen parkinsonism | Q39906818 | ||
| Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-kappaB involvement | Q40313822 | ||
| Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease | Q40358139 | ||
| The cannabinoid dexanabinol is an inhibitor of the nuclear factor-kappa B (NF-kappa B). | Q40513443 | ||
| Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues. | Q40799260 | ||
| Systemic administration of oleoylethanolamide protects from neuroinflammation and anhedonia induced by LPS in rats | Q40877659 | ||
| Enhancement by chlordiazepoxide of catalepsy induced in rats by intravenous or intrapallidal injections of enantiomeric cannabinoids | Q41129946 | ||
| Regulation of a neuronal form of focal adhesion kinase by anandamide | Q41166826 | ||
| Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. | Q41292913 | ||
| Marijuana for parkinsonian tremor | Q41369366 | ||
| Dopamine activation of endogenous cannabinoid signaling in dorsal striatum | Q41646203 | ||
| Serum brain-derived neurotrophic factor levels in different neurological diseases. | Q41811172 | ||
| Cannabinoid receptor agonist protects cultured dopaminergic neurons from the death by the proteasomal dysfunction | Q41968489 | ||
| Detection of cannabinoid receptors CB1 and CB2 within basal ganglia output neurons in macaques: changes following experimental parkinsonism | Q42095959 | ||
| The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide | Q42108464 | ||
| Endocannabinoids in nervous system health and disease: the big picture in a nutshell | Q42112685 | ||
| Dynamic changes of anandamide in the cerebrospinal fluid of Parkinson's disease patients | Q42167232 | ||
| Glutamate spillover drives endocannabinoid production and inhibits GABAergic transmission in the Substantia Nigra pars compacta | Q42450917 | ||
| Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain | Q42451047 | ||
| Cannabinoid (CB(1)), GABA(A) and GABA(B) receptor subunit changes in the globus pallidus in Huntington's disease. | Q42454539 | ||
| Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease | Q42455405 | ||
| Involvement of sphingomyelin hydrolysis and the mitogen-activated protein kinase cascade in the Delta9-tetrahydrocannabinol-induced stimulation of glucose metabolism in primary astrocytes. | Q42463589 | ||
| Expression of the mRNA coding the cannabinoid receptor 2 in the pallidal complex of Macaca fascicularis | Q42471782 | ||
| Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia. | Q42477740 | ||
| Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain | Q42493166 | ||
| Bidirectional plasticity in striatonigral synapses: a switch to balance direct and indirect basal ganglia pathways | Q42497714 | ||
| Δ⁹-tetrahydrocannabinol (Δ⁹-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease. | Q42500348 | ||
| Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson's disease models | Q42508054 | ||
| CB2 cannabinoid receptors promote mouse neural stem cell proliferation. | Q42508956 | ||
| Expression and function of CB1 receptor in the rat striatum: localization and effects on D1 and D2 dopamine receptor-mediated motor behaviors. | Q42520647 | ||
| Involvement of subthalamic nucleus in the stimulatory effect of Delta(9)-tetrahydrocannabinol on dopaminergic neurons | Q42523185 | ||
| The cannabinoid receptor agonist WIN 55,212-2 reduces D2, but not D1, dopamine receptor-mediated alleviation of akinesia in the reserpine-treated rat model of Parkinson's disease | Q42546097 | ||
| Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat. | Q42553964 | ||
| Central and peripheral sites of action for CB₂ receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in rats | Q42585836 | ||
| Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence. | Q42624110 | ||
| Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias. | Q42747563 | ||
| The effects of cannabinoid drugs on abnormal involuntary movements in dyskinetic and non-dyskinetic 6-hydroxydopamine lesioned rats | Q42871461 | ||
| Cannabinoid receptors couple to NMDA receptors to reduce the production of NO and the mobilization of zinc induced by glutamate. | Q42872711 | ||
| Treatment with cannabidiol reverses oxidative stress parameters, cognitive impairment and mortality in rats submitted to sepsis by cecal ligation and puncture. | Q43012779 | ||
| Altered architecture and functional consequences of the mesolimbic dopamine system in cannabis dependence | Q43061541 | ||
| Molecular profiling of a 6-hydroxydopamine model of Parkinson's disease | Q43156838 | ||
| Synaptic activation of kainate receptors gates presynaptic CB(1) signaling at GABAergic synapses | Q43191478 | ||
| BDNF regulates neuronal sensitivity to endocannabinoids | Q43264175 | ||
| Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. | Q43266820 | ||
| Hyperlocomotion and paw tremors are two highly quantifiable signs of SR141716-precipitated withdrawal from delta9-tetrahydrocannabinol in C57BL/6 mice | Q43280499 | ||
| Enhanced striatal glutamate release after the administration of rimonabant to 6-hydroxydopamine-lesioned rats | Q43425029 | ||
| Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease | Q43504648 | ||
| Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications for antinociception | Q43511723 | ||
| Signal transduction interactions between CB1 cannabinoid and dopamine receptors in the rat and monkey striatum. | Q43621342 | ||
| Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures | Q48246173 | ||
| A critical role of the nitric oxide/cGMP pathway in corticostriatal long-term depression. | Q48257417 | ||
| Cannabinoid CB1 and CB2 receptors and fatty acid amide hydrolase are specific markers of plaque cell subtypes in human multiple sclerosis. | Q48257647 | ||
| Brain regional distribution of endocannabinoids: implications for their biosynthesis and biological function | Q48262881 | ||
| Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties | Q48324018 | ||
| Anandamide hydrolysis by human cells in culture and brain | Q48346766 | ||
| Cerebral hypoxia-ischemia and middle cerebral artery occlusion induce expression of the cannabinoid CB2 receptor in the brain | Q48360198 | ||
| Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity | Q48398761 | ||
| Cannabinoid CB1 receptors activation and coactivation with D2 receptors modulate GABAergic neurotransmission in the globus pallidus and increase motor asymmetry | Q48407695 | ||
| Serum levels of brain-derived neurotrophic factor correlate with motor impairment in Parkinson's disease | Q48427629 | ||
| Cannabinoid effects in basal ganglia in a rat model of Parkinson's disease | Q48435185 | ||
| Activation of the CB2 receptor system reverses amyloid-induced memory deficiency | Q48440561 | ||
| Role for neuronal nitric-oxide synthase in cannabinoid-induced neurogenesis | Q48475163 | ||
| Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats | Q48485540 | ||
| Mitochondrial CB₁ receptors regulate neuronal energy metabolism | Q48629492 | ||
| SK channel modulation rescues striatal plasticity and control over habit in cannabinoid tolerance | Q48720514 | ||
| Ultrastructural localization of neuronal brain CB2 cannabinoid receptors. | Q48837860 | ||
| CRIP1a switches cannabinoid receptor agonist/antagonist-mediated protection from glutamate excitotoxicity | Q48914137 | ||
| Oleoylethanolamide reduces L-DOPA-induced dyskinesia via TRPV1 receptor in a mouse model of Parkinson´s disease | Q48923652 | ||
| 5-HT(1A) receptor stimulation and L-DOPA-induced dyskinesia in Parkinson's disease: bridging the gap between serotonergic and glutamatergic mechanisms | Q48961091 | ||
| Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates. | Q43683165 | ||
| Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity | Q43713675 | ||
| Exogenous anandamide protects rat brain against acute neuronal injury in vivo. | Q43792413 | ||
| Cannabinoids reduce levodopa-induced dyskinesia in Parkinson's disease: a pilot study | Q43820144 | ||
| Postsynaptic endocannabinoid release is critical to long-term depression in the striatum | Q43971441 | ||
| CB2 cannabinoid receptor agonist ameliorates Alzheimer-like phenotype in AβPP/PS1 mice. | Q44094824 | ||
| Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. | Q44102387 | ||
| Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease | Q44237885 | ||
| Cannabinoids prevent lipopolysaccharide-induced neurodegeneration in the rat substantia nigra in vivo through inhibition of microglial activation and NADPH oxidase | Q44256125 | ||
| Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with lypopolysaccharide | Q44267931 | ||
| Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat Caudate putamen nucleus. | Q44334367 | ||
| Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism | Q44346123 | ||
| Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia | Q44383212 | ||
| Presynaptic Facilitation of Glutamatergic Synapses to Dopaminergic Neurons of the Rat Substantia Nigra by Endogenous Stimulation of Vanilloid Receptors | Q44418969 | ||
| Intraplantar injection of anandamide inhibits mechanically-evoked responses of spinal neurones via activation of CB2 receptors in anaesthetised rats | Q44519071 | ||
| Evaluation of the efficacy of pramipexole for treating levodopa-induced dyskinesia in patients with Parkinson's disease | Q44570011 | ||
| Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa‐induced dyskinesias | Q44597458 | ||
| Regional changes in type 1 cannabinoid receptor availability in Parkinson's disease in vivo | Q44641132 | ||
| D2 dopamine receptors modulate Galpha-subunit coupling of the CB1 cannabinoid receptor | Q44666474 | ||
| Disruption of endocannabinoid release and striatal long-term depression by postsynaptic blockade of endocannabinoid membrane transport. | Q44770106 | ||
| Involvement of brain-derived neurotrophic factor in cannabinoid receptor-dependent protection against excitotoxicity | Q44840035 | ||
| Evidence for separate neuronal mechanisms for the discriminative stimulus and catalepsy induced by Δ9-THC in the rat | Q44895997 | ||
| Neurokinin B, neurotensin, and cannabinoid receptor antagonists and Parkinson disease | Q44931450 | ||
| Effects on turning of microinjections into basal ganglia of D(1) and D(2) dopamine receptors agonists and the cannabinoid CB(1) antagonist SR141716A in a rat Parkinson's model | Q44933218 | ||
| Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. | Q44963304 | ||
| Defective adult neurogenesis in CB1 cannabinoid receptor knockout mice | Q44987543 | ||
| The cannabinoid CB1 receptor biphasically modulates motor activity and regulates dopamine and glutamate release region dependently | Q45174910 | ||
| Transient receptor potential vanilloid subtype 1 mediates cell death of mesencephalic dopaminergic neurons in vivo and in vitro. | Q45230637 | ||
| The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum. | Q45302088 | ||
| Increased neurogenesis and the ectopic granule cells after intrahippocampal BDNF infusion in adult rats. | Q45310403 | ||
| Cannabinoid CB1 antagonists possess antiparkinsonian efficacy only in rats with very severe nigral lesion in experimental parkinsonism | Q45310537 | ||
| Beneficial effects of a Cannabis sativa extract treatment on diabetes-induced neuropathy and oxidative stress. | Q46013028 | ||
| Increased vulnerability to 6-hydroxydopamine lesion and reduced development of dyskinesias in mice lacking CB1 cannabinoid receptors. | Q46023513 | ||
| The CB(1) antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease. | Q46026291 | ||
| Enhancement of the hypotensive effects of intrathecally injected endocannabinoids by the entourage compound palmitoylethanolamide | Q46087128 | ||
| Natural cannabinoids improve dopamine neurotransmission and tau and amyloid pathology in a mouse model of tauopathy. | Q46123071 | ||
| Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission | Q46146049 | ||
| Early maternal deprivation induces gender-dependent changes on the expression of hippocampal CB(1) and CB(2) cannabinoid receptors of neonatal rats. | Q46179690 | ||
| Dopamine modulation of state-dependent endocannabinoid release and long-term depression in the striatum. | Q46279749 | ||
| Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis. | Q46384445 | ||
| Detailed characterisation of CB2 receptor protein expression in peripheral blood immune cells from healthy human volunteers using flow cytometry | Q46407462 | ||
| Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: new aspects in the pathogenetic mechanisms. | Q46418668 | ||
| Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease | Q46443478 | ||
| A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease | Q46491157 | ||
| Anxiolytic effects in mice of a dual blocker of fatty acid amide hydrolase and transient receptor potential vanilloid type-1 channels. | Q46518412 | ||
| Endocannabinoids mediate neuron-astrocyte communication | Q46682045 | ||
| Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice | Q28343324 | ||
| The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1) | Q28343961 | ||
| The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells | Q28369985 | ||
| Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide | Q28370516 | ||
| Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells | Q28378272 | ||
| Cannabidiol reduces Aβ-induced neuroinflammation and promotes hippocampal neurogenesis through PPARγ involvement | Q28394506 | ||
| Functional CB2 type cannabinoid receptors at CNS synapses | Q28575031 | ||
| Cannabinoids attenuate the effects of aging upon neuroinflammation and neurogenesis | Q28575346 | ||
| Pruning and loss of excitatory synapses by the parkin ubiquitin ligase | Q28576054 | ||
| Postsynaptic localization of CB2 cannabinoid receptors in the rat hippocampus | Q28579094 | ||
| The CB1 cannabinoid receptor signals striatal neuroprotection via a PI3K/Akt/mTORC1/BDNF pathway | Q29306901 | ||
| Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study | Q29615905 | ||
| International Union of Pharmacology. XXVII. Classification of cannabinoid receptors | Q29616832 | ||
| D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons | Q29619181 | ||
| Parkinson's disease. First of two parts | Q29620416 | ||
| Formation and inactivation of endogenous cannabinoid anandamide in central neurons | Q29620558 | ||
| Targeting dopamine D2 and cannabinoid-1 (CB1) receptors in rat nucleus accumbens | Q30499463 | ||
| Postsynaptic TRPV1 triggers cell type–specific long-term depression in the nucleus accumbens | Q30500199 | ||
| RGS4 is required for dopaminergic control of striatal LTD and susceptibility to parkinsonian motor deficits | Q30504550 | ||
| Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice. | Q30506148 | ||
| Cannabinoid receptor activation reduces TNFalpha-induced surface localization of AMPAR-type glutamate receptors and excitotoxicity. | Q30573949 | ||
| Glial A30P alpha-synuclein pathology segregates neurogenesis from anxiety-related behavior in conditional transgenic mice | Q30620210 | ||
| Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk? | Q33211909 | ||
| COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord | Q33235278 | ||
| The role of excitotoxicity in neurodegenerative disease: implications for therapy | Q33639170 | ||
| Parkinson's disease: from molecular pathways in disease to therapeutic approaches | Q33644302 | ||
| Oxidation of the endogenous cannabinoid arachidonoyl ethanolamide by the cytochrome P450 monooxygenases: physiological and pharmacological implications | Q33714587 | ||
| A restricted population of CB1 cannabinoid receptors with neuroprotective activity | Q33730578 | ||
| In vivo pharmacology of endocannabinoids and their metabolic inhibitors: therapeutic implications in Parkinson's disease and abuse liability | Q33751118 | ||
| Cannabinoid control of brain bioenergetics: Exploring the subcellular localization of the CB1 receptor. | Q33765631 | ||
| Cannabis in movement disorders | Q33812356 | ||
| Pharmacological characterization of GPR55, a putative cannabinoid receptor | Q33869340 | ||
| Clinical pharmacology of levodopa-induced dyskinesia. | Q33890292 | ||
| Functional changes of the basal ganglia circuitry in Parkinson's disease. | Q33924857 | ||
| Dopaminergic modulation of endocannabinoid-mediated plasticity at GABAergic synapses in the prefrontal cortex | Q34001324 | ||
| Localization of cannabinoid CB(1) receptor mRNA in neuronal subpopulations of rat striatum: a double-label in situ hybridization study. | Q51976878 | ||
| Anandamide, an endogenous ligand of the cannabinoid receptor, induces hypomotility and hypothermia in vivo in rodents. | Q52060269 | ||
| Endocannabinoid 2-arachidonyl glycerol is a full agonist through human type 2 cannabinoid receptor: antagonism by anandamide. | Q52578470 | ||
| Blockade of 45Ca2+ influx through the N-methyl-D-aspartate receptor ion channel by the non-psychoactive cannabinoid HU-211. | Q55066045 | ||
| Parkinson's disease | Q56877819 | ||
| Overexpression of CB2 cannabinoid receptors results in neuroprotection against behavioral and neurochemical alterations induced by intracaudate administration of 6-hydroxydopamine | Q58866555 | ||
| A role for vanilloid receptor 1 (TRPV1) and endocannabinnoid signalling in the regulation of spontaneous and L-DOPA induced locomotion in normal and reserpine-treated rats | Q60690596 | ||
| Enhancement of Anandamide Formation in the Limbic Forebrain and Reduction of Endocannabinoid Contents in the Striatum of Δ9-Tetrahydrocannabinol-Tolerant Rats | Q60690625 | ||
| A new perspective on cannabinoid signalling: complementary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain | Q64212085 | ||
| The cannabinoid agonists WIN 55,212-2 and CP 55,940 attenuate rotational behavior induced by a dopamine D1 but not a D2 agonist in rats with unilateral lesions of the nigrostriatal pathway | Q70973782 | ||
| Neuroprotective and antioxidant activities of HU-211, a novel NMDA receptor antagonist | Q71583483 | ||
| 45Ca accumulation in rat brain after closed head injury; attenuation by the novel neuroprotective agent HU-211 | Q71798445 | ||
| The endogenous cannabinoid receptor ligand, anandamide, inhibits the motor behavior: role of nigrostriatal dopaminergic neurons | Q72302141 | ||
| Different mechanisms for dopaminergic excitation induced by opiates and cannabinoids in the rat midbrain | Q73101567 | ||
| Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand | Q74219879 | ||
| Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys | Q80609691 | ||
| Endocannabinoids and traumatic brain injury | Q81478373 | ||
| Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study | Q81630893 | ||
| Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation | Q82486794 | ||
| Long-term antidyskinetic efficacy of amantadine in Parkinson's disease | Q83112596 | ||
| Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety | Q83486811 | ||
| Maternal exposure to the CB1 cannabinoid agonist WIN 55212-2 produces robust changes in motor function and intrinsic electrophysiological properties of cerebellar Purkinje neurons in rat offspring | Q85244258 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | cannabinoids | Q422936 |
| basal ganglia | Q464210 | ||
| nervous system | Q9404 | ||
| hydrocarbon | Q43648 | ||
| Parkinson's disease | Q11085 | ||
| neuroprotective agent | Q50377190 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 17 | |
| P577 | publication date | 2015-04-08 | |
| P1433 | published in | Molecular Neurodegeneration | Q15817329 |
| P1476 | title | Promising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection | |
| P478 | volume | 10 |
| Q52587860 | 2-Pentadecyl-2-Oxazoline Reduces Neuroinflammatory Environment in the MPTP Model of Parkinson Disease. |
| Q42087548 | A Humanized Clinically Calibrated Quantitative Systems Pharmacology Model for Hypokinetic Motor Symptoms in Parkinson's Disease |
| Q51539430 | An Information Theoretical Study of the Epistasis Between the CNR1 1359 G/A Polymorphism and the Taq1A and Taq1B DRD2 Polymorphisms: Assessing the Susceptibility to Cannabis Addiction in a Turkish Population. |
| Q64073287 | Cannabinoid Actions on Neural Stem Cells: Implications for Pathophysiology |
| Q61449210 | Contribution of Nrf2 Modulation to the Mechanism of Action of Analgesic and Anti-inflammatory Drugs in Pre-clinical and Clinical Stages |
| Q90699673 | Crosstalk Between the Gut Microbiome and Bioactive Lipids: Therapeutic Targets in Cognitive Frailty |
| Q64811535 | Current Drugs and Potential Future Neuroprotective Compounds for Parkinson's Disease |
| Q52148259 | Deletion of G-protein-coupled receptor 55 promotes obesity by reducing physical activity. |
| Q47192906 | Do psychoactive drugs have a therapeutic role in compulsivity? Studies on schedule-induced polydipsia. |
| Q90191256 | Druggable targets of the endocannabinoid system: Implications for the treatment of HIV-associated neurocognitive disorder |
| Q28073686 | Dysregulation of Ubiquitin-Proteasome System in Neurodegenerative Diseases |
| Q26778885 | Emerging drugs of abuse: current perspectives on synthetic cannabinoids |
| Q37512670 | Marijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy. |
| Q92028537 | Metal Chelation Therapy and Parkinson's Disease: A Critical Review on the Thermodynamics of Complex Formation between Relevant Metal Ions and Promising or Established Drugs |
| Q38832042 | Neuroprotective Effect Is Driven Through the Upregulation of CB1 Receptor in Experimental Autoimmune Encephalomyelitis |
| Q39421016 | Polyunsaturated fatty acids and endocannabinoids in health and disease. |
| Q41829602 | Quantitative proteomics analysis of zebrafish exposed to sub-lethal dosages of β-methyl-amino-L-alanine (BMAA). |
| Q38725907 | Scoparone Inhibits LPS-Simulated Inflammatory Response by Suppressing IRF3 and ERK in BV-2 Microglial Cells. |
| Q64254283 | Structural Insights into CB1 Receptor Biased Signaling |
| Q99615888 | The effect of intra-striatal administration of GPR55 agonist (LPI) and antagonist (ML193) on sensorimotor and motor functions in a Parkinson's disease rat model |
| Q89771533 | The impact of proteostasis dysfunction secondary to environmental and genetic causes on neurodegenerative diseases progression and potential therapeutic intervention |
| Q55397242 | Therapeutic potential of medicinal marijuana: an educational primer for health care professionals. |
Search more.